For the Inventor, By the Inventor

Enter assignee name

Seattle, WA, United States of America

Immune Design Corp.

Calculating rank

USPTO Granted Patents = 16

% Expired Patents = 18.8

EPO Patents = 11

Forward Citations = 80

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Jan Henrik Ter Meulen (7 out of 9 patents)

Thomas W Dubensky, Jr (5 out of 53 patents)

Peter Lars Aksel Berglund (4 out of 4 patents)

4. Carlos V Paya Cuenca (4 out of 4 patents)

5. Scott H Robbins (4 out of 4 patents)

6. Christopher James Nicolai (3 out of 4 patents)

7. Nancy Ann Hosken (3 out of 24 patents)

8. Margaret Dow Moore (3 out of 19 patents)

9. Semih Ullah Tareen (3 out of 10 patents)

10. Tinglan Tina Albershardt (1 out of 1 patent)

11. Neal Van Hoeven (1 out of 8 patents)

12. Jacob Freeman Archer (1 out of 3 patents)

13. Tsai-Yu Lin (1 out of 1 patent)

14. Jin Zhong Li (1 out of 1 patent)

15. Derek D Sloan (1 out of 1 patent)

16 patents: Sort by Forward Citations

1. 11365230 - Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof (2022-06-21),

2. 11135283 - Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids (2021-10-05),

3. 10993956 - GLA monotherapy for use in cancer treatment (2021-05-04),

4. 10584356 - Multigenome retroviral vector preparations and methods and systems for producing and using same (2020-03-10),

5. 10391164 - Vaccines for HSV-2 (2019-08-27),

6. 10391157 - Materials and methods for producing improved lentiviral vector particles (2019-08-27),

7. 10342815 - GLA monotherapy for use in cancer treatment (2019-07-09),

8. 10179919 - Multigenome retroviral vector preparations and methods and systems for producing and using same (2019-01-15),

9. 9895435 - Vaccines for HSV-2 (2018-02-20),

10. 9713635 - Materials and methods for producing improved lentiviral vector particles (2017-07-25),

11. 9555099 - Vaccines for HSV-2 (2017-01-31),

12. 9044420 - Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses (2015-06-02),

13. 8962593 - GLA monotherapy for use in cancer treatment (2015-02-24),

14. 8957047 - GLA monotherapy for use in cancer treatment (2015-02-17),

15. 8323662 - Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein (2012-12-04),

Company Overview

Immune Design Corp. is a biotechnology company based in Seattle, WA, specializing in the development of innovative immunotherapy solutions for cancer and infectious diseases. The organization focuses on harnessing the power of the immune system to create targeted therapies that enhance the body's natural defenses. With a commitment to advancing the field of immuno-oncology, Immune Design is engaged in cutting-edge research and development, aiming to provide transformative treatment options for patients worldwide.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

16 Patents

#122 in Seattle, WA

#436 in Washington

#19,944 in US

#37,887 in the World

Seattle, WA, United States of America

Immune Design Corp.

Forward Citations = 80

16 inventors:

Jan Henrik Ter Meulen (7 out of 9 patents)

Thomas W Dubensky, Jr (5 out of 53 patents)

Peter Lars Aksel Berglund (4 out of 4 patents)

4. Carlos V Paya Cuenca (4 out of 4 patents)

5. Scott H Robbins (4 out of 4 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immune Design Corp.. Retrieved from https://idiyas.com/company/immune-design

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…